ovarian cancer

Preliminary phase 2 results from the REJOICE-Ovarian01 trial show raludotatug deruxtecan (R-DXd) demonstrates clinically significant response in recurrent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. The study observed a 50.5% objective response rate across all doses. The Phase 3 portion will evaluate a 5.6 mg/kg dose of R-DXd against chemotherapy. R-DXd, a CDH6-directed antibody drug conjugate, is being jointly developed by Daiichi Sankyo and Merck, highlighting collaborative efforts in oncology drug development due to high unmet needs in late stage ovarian cancer.

Corcept Therapeutics presented Phase 3 ROSELLA trial data at ESMO 2025, showing relacorilant plus nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer patients, including those progressing on PARP inhibitors. The combination also demonstrated a favorable safety profile. Corcept is expanding the Phase 2 BELLA trial to include platinum-sensitive ovarian and endometrial cancer arms, with initial results expected in late 2026. The FDA has granted relacorilant priority review for platinum-resistant ovarian cancer with a PDUFA date of July 11, 2026.

The KEYNOTE-B96 Phase 3 trial demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with KEYTRUDA plus chemotherapy with or without bevacizumab in platinum-resistant recurrent ovarian cancer. The study showed PFS benefits in the overall population and OS benefits in patients with PD-L1 expressing tumors. The FDA has granted priority review to Merck’s sBLA for this combination, with a PDUFA date of Feb. 20, 2026, potentially changing treatment for this challenging disease.

Molecular Partners, in collaboration with Orano Med, is advancing its Radio-DARPin candidate, MP0726, which targets mesothelin (MSLN) for ovarian cancer treatment. Preclinical data reveals promising tumor accumulation and favorable biodistribution, including a high tumor-to-kidney ratio. The program leverages Molecular Partners’ Radio-DARPin platform, designed to improve the delivery of radioactive payloads to solid tumors. MP0726’s preclinical data is to be presented at the 2025 SNMMI Annual Meeting.